Found 79 of ic50 for monomerid = 50300690 TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.00200nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
3D Structure (crystal)TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.00200nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.236nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.236nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.510nMAssay Description:Inhibition of human FLT3 using EAIYAAPFAKKK substrate and [gamma-33P]-ATP by radiometric biochemical kinase assayMore data for this Ligand-Target Pair
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.623nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.900nMAssay Description:Inhibition of FLT3 ITD mutant (unknown orgin) by ADP-glo kinase assayMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 1.10nMAssay Description:Inhibition of FLT3-ITD autophosphorylation in human MV4-11 cells measured after 2 hrs by Western blot analysisMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 1.10nMAssay Description:Inhibition of FLT3 autophosphorylation in human RS4-11 cells preincubated for 2 hrs followed by FLT3 ligand addition and measured after 15 minsMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human partial length FLT3 ITD mutant expressed in bacterial expression system by Kinomescan methodMore data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 1.93nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 2nMAssay Description:Inhibition of FLT3 autophosphorylation in human AML cells isolated from relapsed acute myeloid leukemia patient by Western blottingMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 2nMAssay Description:Competitive inhibition of FLT3 ITD mutant (unknown origin) in presence of ATPMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 2.06nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 2.06nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 2.60nMAssay Description:Inhibition of FLT3-ITD mutant (unknown origin) using Poly (Glu,Tyr) 4:1 as substrate incubated for 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 3nMAssay Description:Inhibition of FLT3 ITD mutant (unknown origin) expressed in mouse BaF3 cellsMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 4.10nMAssay Description:Inhibition of wild type FLT3 (unknown origin) by ADP-glo kinase assayMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 4.20nMAssay Description:Inhibition of FLT3 (unknown origin) (592 to 969 residues)More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 4.20nMAssay Description:Inhibition of wild-type human partial length FLT3 (V592 to Y969 residues) expressed in bacterial expression system by Kinomescan methodMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 4.20nMAssay Description:Inhibition of human FLT3 ITD mutant EAIYAAPFAKKK peptide as substrate in presence of 33P-gamma ATP by hotspot kinase assayMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 4.20nMAssay Description:Inhibition of FLT3 autophosphorylation in human RS4-11 cells measured after 2 hrs by Western blot analysisMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 4.20nMAssay Description:Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assayMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 4.80nMAssay Description:Inhibition of FLT3 (unknown origin) using Poly (Glu,Tyr) 4:1 as substrate incubated for 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 6.5nMAssay Description:Inhibition of FLT3 ITD mutant (unknown origin)More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 7.40nMAssay Description:Inhibition of recombinant human FLT3 (564 to end residues) using EAIYAAPFAKKK as substrate measured after 40 mins in presence of [gamma-33P]-ATP by s...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 10nMAssay Description:Inhibition of N-terminal GST/His6-fused recombinant human FLT3 (R571 to S993 residues) ITD mutant expressed in Sf9 insect cells using poly (Ala,Glu,L...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 10nMAssay Description:Inhibition of FLT3 ITD mutant (unknown origin)More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 12nMAssay Description:Inhibition of human FLT3 ITD mutant using EAIYAAPFAKKK as substrate preincubated for 20 mins followed by 33P-ATP addition and measured after 2 hrs by...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 13.8nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 13.8nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 15.9nMAssay Description:In the experiments of in vitro enzymatic activity, the IC50 values of Compound 33, Compound 30, Compound 14, Compound 20, Compound 22, Compound 23, C...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 20nMAssay Description:Inhibition of recombinant human N-terminal GST/His6-tagged FLT3 ITD mutant (571 to 993 residues) expressed in Sf9 cells using Tyr2 peptide as substra...More data for this Ligand-Target Pair
Affinity DataIC50: 20.7nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: 20.7nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 26nMAssay Description:Inhibition of N-terminal GST-tagged recombinant human wild-type FLT3 (564 to end residues) expressed in baculovirus infected sf21 cells using Abltide...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 26nMAssay Description:Inhibition of recombinant human FLT3 expressed in insect Sf21 cells preincubated for 15 mins followed by poly(Glu:Tyr) substrate addition for 30 mins...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 30nMAssay Description:Inhibition of human HL60 cells-derived His-tagged FLT3 (564 to 993 residues) expressed in baculovirus infected sf9 cells using poly (4:1 Glu, Tyr) as...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 30nMAssay Description:Inhibition of FLT3 ITD mutant (unknown origin) using TAMRA-Src-tide as substrate measured after 1 hr in presence of ATP at its Km concentration by IM...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 36nMAssay Description:Inhibition of N-terminal GST/His6-fused recombinant wild type human FLT3 (R571 to S993 residues) expressed in Sf9 insect cells using poly (Ala,Glu,Ly...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 37.8nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 37.8nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 39nMAssay Description:Inhibition of FLT3 (unknown origin) using FAM-EPLYWSFPA as substrate preincubated for 60 mins followed by substrate addition by microfluidics assay i...More data for this Ligand-Target Pair
Affinity DataIC50: 42nMAssay Description:Inhibition of recombinant human 3C cleavage site/N-terminal GST-His6 fused PDGFR alpha C-terminal fragment (Q551 to L1089 residues) harboring V561D m...More data for this Ligand-Target Pair
Affinity DataIC50: 42nMAssay Description:Inhibition of PDGFRalpha (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 57.8nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: 57.8nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
